Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

24/07/2019 Port de Barcelona will have a rolling highway terminal 04/07/2019 New software to promote urban district heating and cooling networks 07/06/2019 Biodiversity in danger: Barcelona Synchrotron Park’s actions 28/05/2019 The UAB ranks first according to the CYD Foundation 23/05/2019 Alba: open day, workshop and last results 25/04/2019 The UAB Scientific and Technical Services: an opportunity for BSP’s companies
3 4 5 6 7 8 9 10 11 12 13